Empagliflozin improves cardiac energetics during ischaemia/reperfusion by directly increasing cardiac ketone utilization

Abstract Aims Empagliflozin (EMPA), a potent inhibitor of the renal sodium–glucose cotransporter 2 and an effective treatment for Type 2 diabetes, has been shown to have cardioprotective effects, independent of improved glycaemic control. Several non-canonical mechanisms have been proposed to explai...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cardiovascular research 2023-12, Vol.119 (16), p.2672-2680
Hauptverfasser:	Chase, Dylan, Eykyn, Thomas R, Shattock, Michael J, Chung, Yu Jin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Triphosphate - metabolism Animals Diabetes Mellitus, Type 2 Editor's Choice Glucose Ischemia Original Rats Reperfusion
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!